These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28495277)

  • 1. Poorly specified fasting conditions in clinical research could lead to treatment failure.
    Lubberman FJE; Burger D; van Erp NP
    Lancet Oncol; 2017 May; 18(5):571-573. PubMed ID: 28495277
    [No Abstract]   [Full Text] [Related]  

  • 2. Food effects on oral agents.
    Lewis LD
    Clin Adv Hematol Oncol; 2007 Aug; 5(8):589-90. PubMed ID: 17982397
    [No Abstract]   [Full Text] [Related]  

  • 3. Food and oral antineoplastics: more than meets the eye.
    Jain RK; Brar SS; Lesko LJ
    Clin Cancer Res; 2010 Sep; 16(17):4305-7. PubMed ID: 20736331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 6. Tilting the balance of dose modification for oral anticancer drugs?
    Bedard PL; Siu LL
    J Clin Oncol; 2014 May; 32(15):1537-9. PubMed ID: 24711547
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of diet on the clinical pharmacology of oral antineoplastic agents.
    Ruggiero A; Cefalo MG; Coccia P; Mastrangelo S; Maurizi P; Riccardi R
    Eur J Clin Pharmacol; 2012 Feb; 68(2):115-22. PubMed ID: 21796375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food Effect Studies for Oncology Drug Products.
    Parsad S; Ratain MJ
    Clin Pharmacol Ther; 2017 May; 101(5):606-612. PubMed ID: 28073144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navelbine: a new step in cancer therapy?
    Armand JP; Marty M
    Semin Oncol; 1989 Apr; 16(2 Suppl 4):41-5. PubMed ID: 2652319
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutics: clinical trials--a review of terms and principles: part I.
    Reich SD
    Cancer Nurs; 1982 Jun; 5(3):232-3. PubMed ID: 6919461
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer research. Can fasting blunt chemotherapy's debilitating side effects?
    Couzin J
    Science; 2008 Aug; 321(5893):1146-7. PubMed ID: 18755948
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
    Prasad V; Massey PR; Fojo T
    J Clin Oncol; 2014 May; 32(15):1620-9. PubMed ID: 24711558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of food effects for oral oncology drugs.
    Ratain MJ
    Clin Adv Hematol Oncol; 2012 Jun; 10(6):397-8. PubMed ID: 22895243
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trials and drug approvals continue to accelerate in China.
    Wang M
    Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
    [No Abstract]   [Full Text] [Related]  

  • 15. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.
    Hucl T; Gallmeier E; Kern SE
    Cell Cycle; 2007 Jun; 6(11):1336-41. PubMed ID: 17568192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
    Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
    J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
    [No Abstract]   [Full Text] [Related]  

  • 19. Significance of natural product interactions in oncology.
    Block KI
    Integr Cancer Ther; 2013 Jan; 12(1):4-6. PubMed ID: 23188923
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
    Scheulen ME; Saito K; Hilger RA; Mende B; Zergebel C; Strumberg D
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):753-61. PubMed ID: 22020317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.